Rybrevant (amivantamab-vmjw) was approved for adults with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, the U.S. Food and Drug Administration announced Friday.
May 26, 2021
0
1
Patients with advanced colorectal cancer may be spared from a toxic side effect caused by a type of targeted therapy used to treat the cancer with the help of another drug normally used to treat melanoma, according to a study ...
Apr 28, 2021
0
10
Conjunctival tissue is perhaps most recognizable to the average person in relation to conjunctivitis—but it's a vital part of the eye's functionality and protection. In a new study, researchers from Osaka University generated ...
Feb 2, 2021
0
13
There is currently no cure for osteoarthritis, but a group of scientists believe they've discovered a method through which a simple knee injection could potentially stop the disease's effects. These researchers showed that ...
Jan 15, 2021
0
233
Researchers at McGill University have identified a new cellular pathway that limits the growth and spread of brain tumors by controlling the recycling of cell surface receptor proteins. The study, which will be published ...
Jan 14, 2021
0
6
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination—of irinotecan, ...
Dec 24, 2020
0
15
Tagrisso (osimertinib) received approval as an adjuvant treatment for patients with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, the U.S. Food and Drug ...
Dec 23, 2020
0
5
The absence of a protein that works to prevent tumor formation may explain why some patients are resistant to a common cancer therapy, according to Penn State College of Medicine researchers. They said that testing cancers ...
Dec 21, 2020
0
13
Personalized treatment options for patients with lung cancer have come a long way in the past two decades. For patients with non-small cell lung cancer, the most common subtype of lung cancer and the leading cause of cancer-related ...
Oct 16, 2020
0
45
The effectiveness of cancer treatment is often hampered by cancer cells being heterogeneous. This is the case for EGFR-mutated lung cancer: drugs based on biomolecules of a type known as tyrosine kinase inhibitor (TKI) have ...
Oct 5, 2020
0
6
